At Coherus, we put patients first.

We are dedicated to improving the availability of high-value, high-quality therapeutics. Our pipeline and product portfolio spans multiple therapeutic areas including oncology, immunology, and ophthalmology.

We market UDENYCA^® (pegfilgrastim-cbqv), a biosimilar of Neulasta^® in the U.S., and plan to launch Lucentis^® biosimilar CIMERLI™ (ranibizumab-eqrn) in the U.S. in early October 2022, as well as the FDA-approved Humira^® biosimilar YUSIMRY™ (adalimumab-aqvh) in the U.S. in 2023.

In 2021, we in-licensed toripalimab, an anti-PD-1 antibody, in the United States and Canada. A biologics license application for toripalimab for the treatment of nasopharyngeal carcinoma is under review by the FDA with a target action date of December 23, 2022.

Our strategy is to invest cash flows from our commercial biosimilar business to build a fast-follower immuno-oncology franchise that will be synergistic with our proven commercial capabilities in oncology.